However, TUSC3 methylation per se did not contribute to patient survival (S10), confirming our findings that TUSC3 silencing occurs already in benign adenomas and on the protein level predicts prognosis only at early stage CRC but not in advanced mCRC. Here, TUSC3 is linked to adenoma.